Fortrea signals stabilization as backlog hits $7.8B
Compartilhar
Fortrea (NASDAQ:FTRE) reported a steady start to 2026, characterized by robust new business wins and a growing backlog that provides a solid foundation for the company as it navigates its second full year as a standalone clinical research organization (CRO).
